U.S. Markets close in 1 hr 51 mins
  • S&P 500

    +8.71 (+0.23%)
  • Dow 30

    +9.40 (+0.03%)
  • Nasdaq

    +41.21 (+0.36%)
  • Russell 2000

    -17.03 (-0.98%)
  • Crude Oil

    -1.40 (-1.41%)
  • Gold

    -29.60 (-1.68%)
  • Silver

    -0.03 (-0.14%)

    -0.0075 (-0.7340%)
  • 10-Yr Bond

    +0.0930 (+3.31%)
  • Vix

    -0.16 (-0.58%)

    -0.0016 (-0.1337%)

    -0.0940 (-0.0692%)

    +571.34 (+2.90%)
  • CMC Crypto 200

    +2.35 (+0.54%)
  • FTSE 100

    +82.30 (+1.17%)
  • Nikkei 225

    -315.82 (-1.20%)

Is Harrow Health, Inc.'s(NASDAQ:HROW) Recent Stock Performance Tethered To Its Strong Fundamentals?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Harrow Health's (NASDAQ:HROW) stock is up by a considerable 24% over the past month. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. In this article, we decided to focus on Harrow Health's ROE.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.

See our latest analysis for Harrow Health

How Is ROE Calculated?

Return on equity can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Harrow Health is:

35% = US$9.7m ÷ US$28m (Based on the trailing twelve months to March 2021).

The 'return' is the profit over the last twelve months. One way to conceptualize this is that for each $1 of shareholders' capital it has, the company made $0.35 in profit.

What Is The Relationship Between ROE And Earnings Growth?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes.

Harrow Health's Earnings Growth And 35% ROE

Firstly, we acknowledge that Harrow Health has a significantly high ROE. Additionally, the company's ROE is higher compared to the industry average of 23% which is quite remarkable. As a result, Harrow Health's exceptional 32% net income growth seen over the past five years, doesn't come as a surprise.

We then compared Harrow Health's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 19% in the same period.


Earnings growth is a huge factor in stock valuation. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. Is Harrow Health fairly valued compared to other companies? These 3 valuation measures might help you decide.

Is Harrow Health Using Its Retained Earnings Effectively?


Overall, we are quite pleased with Harrow Health's performance. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. Having said that, the company's earnings growth is expected to slow down, as forecasted in the current analyst estimates. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.